List of Tables
Table 1. Global Myelofibrosis Targeted Drug Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Myelofibrosis Targeted Drug Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Myelofibrosis Targeted Drug Market Competitive Situation by Manufacturers in 2025
Table 4. Global Myelofibrosis Targeted Drug Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Myelofibrosis Targeted Drug Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Myelofibrosis Targeted Drug Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Myelofibrosis Targeted Drug Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Myelofibrosis Targeted Drug Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Myelofibrosis Targeted Drug, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Myelofibrosis Targeted Drug, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Myelofibrosis Targeted Drug, Product Types and Applications
Table 12. Global Key Manufacturers of Myelofibrosis Targeted Drug, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Myelofibrosis Targeted Drug Companies by Tier (Tier 1, Tier 2, Tier 3), based on Myelofibrosis Targeted Drug Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Myelofibrosis Targeted Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Myelofibrosis Targeted Drug Sales by Region (K Units), 2021–2026
Table 18. Global Myelofibrosis Targeted Drug Sales Market Share by Region (2021–2026)
Table 19. Global Myelofibrosis Targeted Drug Sales by Region (K Units), 2027–2032
Table 20. Global Myelofibrosis Targeted Drug Sales Market Share by Region (2027–2032)
Table 21. Global Myelofibrosis Targeted Drug Revenue by Region (US$ Million), 2021–2026
Table 22. Global Myelofibrosis Targeted Drug Revenue Market Share by Region (2021–2026)
Table 23. Global Myelofibrosis Targeted Drug Revenue by Region (US$ Million), 2027–2032
Table 24. Global Myelofibrosis Targeted Drug Revenue Market Share by Region (2027–2032)
Table 25. North America Myelofibrosis Targeted Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Myelofibrosis Targeted Drug Sales by Country (K Units), 2021–2026
Table 27. North America Myelofibrosis Targeted Drug Sales by Country (K Units), 2027–2032
Table 28. North America Myelofibrosis Targeted Drug Revenue by Country (US$ Million), 2021–2026
Table 29. North America Myelofibrosis Targeted Drug Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Myelofibrosis Targeted Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Myelofibrosis Targeted Drug Sales by Country (K Units), 2021–2026
Table 32. Europe Myelofibrosis Targeted Drug Sales by Country (K Units), 2027–2032
Table 33. Europe Myelofibrosis Targeted Drug Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Myelofibrosis Targeted Drug Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Myelofibrosis Targeted Drug Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Myelofibrosis Targeted Drug Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Myelofibrosis Targeted Drug Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Myelofibrosis Targeted Drug Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Myelofibrosis Targeted Drug Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Myelofibrosis Targeted Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Myelofibrosis Targeted Drug Sales by Country (K Units), 2021–2026
Table 42. Latin America Myelofibrosis Targeted Drug Sales by Country (K Units), 2027–2032
Table 43. Latin America Myelofibrosis Targeted Drug Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Myelofibrosis Targeted Drug Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Myelofibrosis Targeted Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Myelofibrosis Targeted Drug Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Myelofibrosis Targeted Drug Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Myelofibrosis Targeted Drug Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Myelofibrosis Targeted Drug Revenue by Country (US$ Million), 2027–2032
Table 50. Global Myelofibrosis Targeted Drug Sales (K Units) by Type (2021–2026)
Table 51. Global Myelofibrosis Targeted Drug Sales (K Units) by Type (2027–2032)
Table 52. Global Myelofibrosis Targeted Drug Sales Market Share by Type (2021–2026)
Table 53. Global Myelofibrosis Targeted Drug Sales Market Share by Type (2027–2032)
Table 54. Global Myelofibrosis Targeted Drug Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Myelofibrosis Targeted Drug Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Myelofibrosis Targeted Drug Revenue Market Share by Type (2021–2026)
Table 57. Global Myelofibrosis Targeted Drug Revenue Market Share by Type (2027–2032)
Table 58. Global Myelofibrosis Targeted Drug Price (US$/Unit) by Type (2021–2026)
Table 59. Global Myelofibrosis Targeted Drug Price (US$/Unit) by Type (2027–2032)
Table 60. Global Myelofibrosis Targeted Drug Sales (K Units) by Application (2021–2026)
Table 61. Global Myelofibrosis Targeted Drug Sales (K Units) by Application (2027–2032)
Table 62. Global Myelofibrosis Targeted Drug Sales Market Share by Application (2021–2026)
Table 63. Global Myelofibrosis Targeted Drug Sales Market Share by Application (2027–2032)
Table 64. Global Myelofibrosis Targeted Drug Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Myelofibrosis Targeted Drug Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Myelofibrosis Targeted Drug Revenue Market Share by Application (2021–2026)
Table 67. Global Myelofibrosis Targeted Drug Revenue Market Share by Application (2027–2032)
Table 68. Global Myelofibrosis Targeted Drug Price (US$/Unit) by Application (2021–2026)
Table 69. Global Myelofibrosis Targeted Drug Price (US$/Unit) by Application (2027–2032)
Table 70. Novartis Company Information
Table 71. Novartis Description and Business Overview
Table 72. Novartis Myelofibrosis Targeted Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Novartis Myelofibrosis Targeted Drug Product
Table 74. Novartis Recent Developments/Updates
Table 75. Celgene Company Information
Table 76. Celgene Description and Business Overview
Table 77. Celgene Myelofibrosis Targeted Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Celgene Myelofibrosis Targeted Drug Product
Table 79. Celgene Recent Developments/Updates
Table 80. Incyte Company Information
Table 81. Incyte Description and Business Overview
Table 82. Incyte Myelofibrosis Targeted Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Incyte Myelofibrosis Targeted Drug Product
Table 84. Incyte Recent Developments/Updates
Table 85. Zelgen Company Information
Table 86. Zelgen Description and Business Overview
Table 87. Zelgen Myelofibrosis Targeted Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Zelgen Myelofibrosis Targeted Drug Product
Table 89. Zelgen Recent Developments/Updates
Table 90. Key Raw Materials Lists
Table 91. Raw Materials Key Suppliers Lists
Table 92. Myelofibrosis Targeted Drug Distributors List
Table 93. Myelofibrosis Targeted Drug Customers List
Table 94. Myelofibrosis Targeted Drug Market Trends
Table 95. Myelofibrosis Targeted Drug Market Drivers
Table 96. Myelofibrosis Targeted Drug Market Challenges
Table 97. Myelofibrosis Targeted Drug Market Restraints
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
Table 101. Authors List of This Report
List of Figures
Figure 1. Product Picture of Myelofibrosis Targeted Drug
Figure 2. Global Myelofibrosis Targeted Drug Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Myelofibrosis Targeted Drug Market Share by Type: 2025 & 2032
Figure 4. Ruxolitinib Product Picture
Figure 5. Jaktinib Product Picture
Figure 6. Fedratinib Product Picture
Figure 7. Pacritinib Product Picture
Figure 8. Others Product Picture
Figure 9. Global Myelofibrosis Targeted Drug Market Value by Application (US$ Million), 2021–2032
Figure 10. Global Myelofibrosis Targeted Drug Market Share by Application: 2025 & 2032
Figure 11. Primary Myelofibrosis
Figure 12. Secondary Myelofibrosis
Figure 13. Global Myelofibrosis Targeted Drug Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Myelofibrosis Targeted Drug Market Size (US$ Million), 2021–2032
Figure 15. Global Myelofibrosis Targeted Drug Sales (K Units), 2021–2032
Figure 16. Global Myelofibrosis Targeted Drug Average Price (US$/Unit), 2021–2032
Figure 17. Myelofibrosis Targeted Drug Report Years Considered
Figure 18. Myelofibrosis Targeted Drug Sales Share by Manufacturers in 2025
Figure 19. Global Myelofibrosis Targeted Drug Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Myelofibrosis Targeted Drug Players: Market Share by Revenue in Myelofibrosis Targeted Drug in 2025
Figure 21. Myelofibrosis Targeted Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Myelofibrosis Targeted Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Myelofibrosis Targeted Drug Sales Market Share by Country (2021–2032)
Figure 24. North America Myelofibrosis Targeted Drug Revenue Market Share by Country (2021–2032)
Figure 25. United States Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Myelofibrosis Targeted Drug Sales Market Share by Country (2021–2032)
Figure 28. Europe Myelofibrosis Targeted Drug Revenue Market Share by Country (2021–2032)
Figure 29. Germany Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Myelofibrosis Targeted Drug Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Myelofibrosis Targeted Drug Revenue Market Share by Region (2021–2032)
Figure 36. China Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Myelofibrosis Targeted Drug Sales Market Share by Country (2021–2032)
Figure 44. Latin America Myelofibrosis Targeted Drug Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Myelofibrosis Targeted Drug Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Myelofibrosis Targeted Drug Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Myelofibrosis Targeted Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Myelofibrosis Targeted Drug by Type (2021–2032)
Figure 55. Global Revenue Market Share of Myelofibrosis Targeted Drug by Type (2021–2032)
Figure 56. Global Myelofibrosis Targeted Drug Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Myelofibrosis Targeted Drug by Application (2021–2032)
Figure 58. Global Revenue Market Share of Myelofibrosis Targeted Drug by Application (2021–2032)
Figure 59. Global Myelofibrosis Targeted Drug Price (US$/Unit) by Application (2021–2032)
Figure 60. Myelofibrosis Targeted Drug Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
